|
Early View Articles
Value in Health offers readers the opportunity to access complete articles to be published in upcoming issues of Value in Health. These articles are citable by DOI, and by volume and issue.
Early View Articles can be found at: http://www3.interscience.wiley.com/journal/120174665/issue (click "Early View" next to the issue navigation toolbar) and are scheduled to appear in the following upcoming issues of Value in Health. The final Table of Contents for each issue will be available when the final issue appears online.
Future Issues:
Value in Health January/February 2011 Volume 14
Issue 1
(Note: Access to Early View articles beginning with Volume 14 of Value in Health’s new publisher will be made available soon)
ECONOMIC EVALUATION
Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.
Ewen Cummins, MSc, Christian Asseburg, PhD, Yogesh Punekar, PhD, Emily Shore, MSc, James Morris, MSc, Andrew Briggs, DPhil, Elisabeth Fenwick, PhD
The cost-utility analysis of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: a probabilistic decision model
Olalekan A Uthman, Taiwo Aderemi Popoola, Ismail Yahaya, Mubashir MB Uthman, Olatunde Aremu
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes
Matthias Schwenkglenks, PhD MPH, John E Brazier, PhD, Thomas D Szucs, MD MBA MPH LLM, Keith AA Fox, MB ChB FRCP FESC FMedSci
Preventable Hospital Admissions Related to Medication (HARM): Cost analysis of the HARM-study
Anne J. Leendertse MSc, Patricia M.L.A. van den Bemt, J. Bart Poolman BSc, Lennart J. Stoker PharmD, Antoine C.G. Egberts PhD, Maarten J Postma PhD
Lung cancer treatment costs, including patient responsibility, by stage of disease and treatment modality, 1992-2003
Lauren E. Cipriano, BSc, BA, Dorothy Romanus, RPh, MSc, Craig C. Earle, MD, MSc, Bridget A. Neville, MPH, Elkan F. Halpern, PhD, G. Scott Gazelle, MD, MPH, PhD, Pamela M. McMahon, PhD
The CHD challenge: comparing four cost-effectiveness models
David Turner MSc, James Raftery PhD MA, Keith Cooper PhD MSc, Eleanor Fairbank MSc, Steven Palmer MSc, Sue Ward BA, Roberta Ara MSc
The Economic Burden of Medicare-Eligible Patients by Multiple Sclerosis Type
Dan M Gilden, MS, Joanna Kubisiak, MPH, Arthur S Zbrozek, MS, MBA
COST/EFFECTIVENESS ANALYSIS OF LHRH-AGONISTS IN THE TREATMENT OF METASTATIC PROSTATE CANCER IN ITALY
Iannazzo S, Pradelli L, Carsi M, Perachino M
Analysis of EQ-5D Scores from Two Phase 3 Clinical Trials of Romiplostim in the Treatment of Immune Thrombocytopenia (ITP)
Miguel A. Sanz, MD, Louis Aledort, MD, Susan D. Mathias, MPH, Xuena Wang, PhD, John J. Isitt, MS
Can we account for selection bias? A comparison between bare metal and drug eluting stents
Dr. Annemieke De Ridder, Dr. Diana De Graeve
OUTCOMES ASSESSMENT
ViH-12-2009-0350-OM.R2 Development of a Conceptual Framework and Calibrated Item Banks to Measure Patient Reported Dyspnea Severity and Related Functional Limitations
Seung W. Choi, PhD, David E. Victorson, PhD, Susan Yount, PhD, Susan Anton, DrPh, and David Cella, PhD
Metric properties of the MacDQoL, individualized macular-disease-specific quality of life instrument, and newly identified subscales in French, German, Italian and American populations.
Berdeaux Gilles MD, Mesbah Mounir PhD, Bradley Clare PhD.
Utility Values in NICE Technology Appraisals
Jonathan C Tosh MSc, Louise J Longworth PhD, Elisabeth George PhD
VALUING PHARMACOGENETIC TESTING SERVICES: A COMPARISON OF PATIENTS’ AND HEALTHCARE PROFESSIONALS’ PREFERENCES Katherine Payne, BPharm, MSc, PhD, MRPharmS, Emily A Fargher, BA (Hons), MSc, Stephen A Roberts, PhD, Karen Tricker, BSc(hons) MPM PhD, Rachel A Elliott, BPharm PhD MRPharmS, Julie Ratcliffe, BA (Econ) MSc Health Econ PhD Economics, William G Newman MA MBChB PhD FRCP
Valuing Health Across the Lifespan: Health State Preferences for Seasonal Influenza Illnesses in Patients of Different Ages Lisa A. Prosser, MS, PhD; Katherine Payne, PhD; Donna Rusinak, BA; Ping Shi, MA; Timothy Uyeki, MD, MPH; Mark Messonnier, PhD
Exact Method for Computing Absolute Percentage Change in a Dichotomous Outcome from Meta-Analytic Effect Size: Improving Impact and Cost-Outcome Estimates
Ted R. Miller, PhD, Delia Hendrie, Jim Derzon, PhD
Screenee perception and health-related quality of life in colorectal cancer screening: a review
Elena Pizzo, Alessandro Pezzoli, Reinhold Stockbrugger, Enrico Bracci, Emidia Vagnoni, Sergio Gullini
Is the Health Utilities Index 3 Valid for Patients With Ankylosing Spondylitis?
Katherine Gooch, MAppEpi, David Feeny, PhD, Robert L. Wong, MD, Hartmut Kupper, MD, Aileen L. Pangan, MD, Dennis A. Revicki, PhD, Désirée van der Heijde, MD, PhD
Reconsidering the value of rehabilitation for patients with cerebrovascular disease in Japanese acute health care hospitals.
Kazuaki Kuwabara, MD, MPH, DPH., Shinya Matsuda, MD, PhD, Kiyohide Fushimi, MD, PhD, Koichi B Ishikawa, PhD, Hiromasa Horiguchi, PhD, Kenji Fujimori. MD, PhD
Effect of Subcutaneous Methylnaltrexone on Patient-Reported Constipation Symptoms
Shrividya S. Iyer, PhD; Bruce P. Randazzo, MD,PhD; Evan L. Tzanis; Seth L. Schulman, MD; Haiying Zhang , PhD; Wenjin Wang, PhD; Amy L. Manley
Impact of Angiotensin-Converting Enzyme (ACE) Inhibitors on Mortality and Morbidity in Patients with Acute Myocardial Infarction: Does Tissue Selectivity Matter? Iftekhar Kalsekar, PhD, Julie Koehler, PharmD, John Mulvaney, MH
CORRESPONDANCE
The Value of Budget Impact Analyses in Evaluating Targeted Therapies – The Case of RSV Prophylaxis for Preterm Infants
Leonard Krilov, Deborah Palazzi, Ancilla Fernandes, Robert Klein, Parthiv Mahadevia
Uncertainty analysis is inherently Bayesian
John Stevens
Value in Health December 2010 Volume 13
Issue 8
EDITORIAL
Data Generalizability, Data Transferability and the Political Economy of Pharmacoeconomic Guidelines
Florian Turk
Economic Evaluations Alongside Effectiveness Trials
Joseph D. Jackson, PhD
ECONOMIC EVALUATION
Methods for the collection of resource use data within clinical trials: A systematic review of trials funded by the UK Health Technology Assessment programme
Colin H Ridyard PhD, Dyfrig A Hughes MSc PhD MRPharmS
Use of a Disease-Specific Instrument in Economic Evaluations: Mapping WOMAC onto the EQ-5D Utility Index
Feng Xie, Eleanor M Pullenayegum, Shu-Chuen Li, Robert Hopkins, Julian Thumboo, Ngai-Nung Lo
The value of correcting values: Influence and importance of correcting TTO scores for time preference
Arthur E. Attema, PhD and Werner B.F. Brouwer, PhD
Historical Lifetimes of Drugs in England: Application to Value of Information and Cost-effectiveness Analyses
Martin Hoyle, PhD
Expanded HIV Screening in the U.S.: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis
Erika G. Martin, PhD, MPH, A. David Paltiel, PhD, Rochelle P. Walensky, MD, MPH, Bruce R. Schackman, PhD
Cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals in Mexico
Iris Contreras-Hernandez, MD, MSc, Debbie Becker, MSc, Jeremy Chancellor, MSc, Felicitas Kühne, MSc, Joaquin Mould-Quevedo, PhD, MSc, MBA, Gabriela Vega, MSc, Shalaka Marfatia, B.Pharm, MS, MPH
Cost-effectiveness of Specialized Multi-disciplinary Heart Failure Clinics in Ontario, Canada
Harindra C. Wijeysundera MD, Márcio Machado PhD, Xuesong Wang, Gabrielle van der Velde DC PhD,, Nancy Sikich, William Witteman MIS, Jack V. Tu MD, PhD, Douglas S. Lee MD, PhD, Shaun G. Goodman MD, MSc, Robert Petrella MD, PhD, Martin O’Flaherty MD, MSc, Simon Capewell MD, Murray Krahn MD, MSc
Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B
Helen Dakin, Anthony Bentley, Geoff Dusheiko
OUTCOMES ASSESSMENT
Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naïve patients with chronic hepatitis B
Helen Dakin, Carrie Fidler, and Christie Harper
International development of the Patient Reported Outcome Indices for Multiple Sclerosis (PRIMUS)
Stephen P McKenna PhD, Lynda C Doward MRes, James Twiss BSc, Peter Hagell PhD, Nadia C Oprandi PhD, John Fisk PhD, François Grand’Maison MD, Virender Bhan MD, Txomin Arbizu MD, David Brassat MD, Thomas Kohlmann PhD, David M Meads MSc, Benjamin J Eckert MS
How is evidence on test performance synthesised for economic decision models of diagnostic tests? A systematic appraisal of Health Technology Assessments in the UK since 1997.
Nicola Novielli, B.Sc. M.Sc., Dr Nicola J. Cooper, B.Sc. M.Sc., Ph.D., Professor Keith R. Abrams, B.Sc. M.Sc. Ph.D., Professor Alex J. Sutton, B.Sc. M.Sc. Ph.D.
Recent Trends and Geographic Patterns of the Burden of Disease Attributable to Smoking
Haomiao Jia, PhD, Erica I. Lubetkin, MD, MPH
Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): A Patient-Reported Outcome (PRO)
Nancy Kline Leidy, PhD1; Teresa Wilcox, PhD; P.W. Jones, MD, Lindsey Murray, BA; Randall Winnette, BA; Kellee Howard, MA; Jennifer Petrillo, BS; John Powers, MD; Sanjay Sethi, MD
Network meta-analysis with competing risk outcomes
A E Ades, PhD, Ifigeneia Mavranezouli, MD, MSc, Sofia Dias, PhD, Nicky J Welton, PhD, Craig Whittington, PhD, Tim Kendall, FRCPsych
Functional Impairment and Disability across Mood States in Bipolar Disorder
Adriane R Rosa, PharmD, PhD, María Reinares, PsycD, PhD, Erin E Michalak, MD, PhD, C. Mar Bonnin, PsycD, Brisa Sole, PsycD, Carolina Franco, MD, Mercè Comes, NurseD, Carla Torrent, PsycD, PhD, Flávio Kapczinski, MD, PhD, Eduard Vieta, MD, PhD
The Role of Observational Investigations in Comparative Effectiveness Research
Nicholas F. Marko, MD, Robert J. Weil, MD
Is longer waiting time for Total Knee Replacement associated with health outcomes and medication costs? Randomized clinical trial.
Ulla Tuominen PhD Candidate, Harri Sintonen PhD, Johanna HirvonenPhD, Seppo Seitsalo MD PhD, Pekka Paavolainen MD PhD, Matti Lehto MD PhD, Kalevi Hietaniemi MD, Marja Blom PhD
DISCRETE CHOICE MODELING FOR THE QUANTIFICATION OF HEALTH STATES: THE CASE OF THE EQ-5D
Elly A. Stolk, PhD, Mark Oppe, MSc, Luciana Scalone, PhD,
Paul F.M. Krabbe, PhD
Predicting time trade-off health state valuations of adolescents in four Pacific countries using the Assessment of Quality of Life (AQoL-6D) instrument
Marj Moodie, DRPH, Jeff Richardson, PhD, Bree Rankin, MPH, Angelo Iezzi, M.Counselling, Kompal Sinha
POLICY ANALYSIS
What do international pharmacoeconomic guidelines say about economic data transferability?
Marco Barbieri PhD, Michael Drummond PhD, Frans Rutten PhD, MSc John Cook PhD, Henry A. Glick PhD, Joanna Lis PhD, Msc, Shelby D. Reed PhD, RPh, Mark Sculpher PhD and Johan L Severens PhD, on behalf of the ISPOR Good Research Practices Economic Data Transferability Task Force
Estimating the Effect of Medication Adherence on Health Outcomes Among Patients with Type-2 Diabetes – An Application of Marginal Structural Models
Andrew P. Yu, Ph.D., Yanni F. Yu, M.A., M.S., Michael B. Nichol, Ph.D.
WILLINGNESS TO PAY FOR A QALY: THE INDIVIDUAL PERSPECTIVE
drs. Ana Bobinac, drs. N. Job A. van Exel, prof. dr. Frans F.H. Rutten, prof. dr. Werner B.F. Brouwer
Value in Health September/October 2010 Volume 13
Issue 6
EDITORIAL
ViH Editor-in-Chief Farewell Editorial
Josephine Mauskopf PhD
ECONOMIC EVALUATION
The Modelled Lifetime Cost-Effectiveness of Published Adherence-Improving Interventions for Antihypertensive and Lipid-Lowering Medications
Richard H. Chapman, PhD, Stacey L. Kowal, MSc, Spencer B. Cherry, MBA, Cheryl P. Ferrufino, BA, Craig S. Roberts, PharmD, MPA, Linda Chen, MPhil, MPH
Cost-effectiveness of therapeutic hypothermia to treat neonatal encephalopathy
Dean A Regier, PhD, Stavros Petrou, PhD, Jane Henderson, MSc, Oya Eddama, PhD, Nishma Patel, MSc, Brenda Strohm, RGN, Peter Brocklehurst, MBChB, FRCOG, MSc, FFPH, A David Edwards, MB,BS, FRCP, FRCPCH, FMedSci, Denis Azzopardi, MD, FRCP, FRCPCH
Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada
Karissa M Johnston PhD, Carlo A. Marra PhD, Joseph M Connors MD, Mehdi Najafzadeh MSc, Laurie Sehn MD, Stuart J. Peacock Dphil
The unit costs of inpatient hospital days, outpatient visits and daycare treatments in the field of oncology and haematology
Siok Swan Tan, MSc, Chantal WM van Gils, MSc, Margreet G Franken, MSc, Leona Hakkaart – van Roijen, PhD, Carin A Uyl – de Groot, PhD
Evaluating Willingness to Pay Thresholds for Dementia Caregiving Interventions: Application to the Tailored Activity Program
Eric Jutkowitz, BA; Laura N. Gitlin, PhD; Laura T. Pizzi, PharmD, MPH
Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom: Findings from the INFORCE Study
John Reckless, MD, Glenn Davies, DrPH, Kaan Tunceli, PhD, X. Henry Hu, MD, PhD, and Philippe Brudi, MD
The Cost-effectiveness of Spinal Cord Stimulation for Complex Regional Pain Syndrome
Marius A.Kemler MD, PhD, Jon H.Raphael MD, Anthony Bentley, Rod S.Taylor PhD
Willingness to Pay for Lung Cancer Treatment
Hui-Chu Lang Ph.D
Modeling the long-term cost-effectiveness of the Caries Management System in an Australian population
Emma Warren, Christine Pollicino, Bradley Curtis, Wendell Evans, Alexandra Sbaraini, Eli Schwarz
AN OUNCE OF PREVENTION IS WORTH A POUND OF CURE: A COST-EFFECTIVENESS ANALYSIS OF INCIDENTALLY DETECTED ANEURYSMS IN FUNCTIONAL MRI RESEARCH
Mohsen Sadatsafavi, MD, MHSc. David Li, MD, Judy Illes, PhD., Carlo Marra, PhD
A MULTI-MARKER APPROACH FOR THE PREDICTION OF CORONARY ARTERY DISEASE: COST-EFFECTIVNESS ANALYSIS
Dragana Lakić, BPharm, Nataša Bogavac-Stanojević. PhD, Zorana Jelić-Ivanović, PhD, Jelena Kotur-Stevuljević, PhD, Slavica Spasić, PhD, Mitja Kos, PhD
OUTCOMES ASSESSMENT
Differences in child versus parent reports of the child's health-related quality of life in children with epilepsy and healthy siblings
Christine Bower Baca, MD, B.G. Vickrey, MD, MPH, Ron D. Hays, PhD, Stefanie D. Vassar, MS, and Anne T. Berg, PhD
Clustering Rasch results: A novel method for developing rheumatoid arthritis states for use in valuation studies
Helen M. McTaggart-Cowan, M.Sc., John E. Brazier, Ph.D., Aki Tsuchiya, Ph.D.
A competing risks prescription refill model of compliance and persistence
Dr. T. Ian Barron, PhD, Dr. Kathleen Bennett, PhD, Professor John Feely MD, FRCPI, FRCPE, FRCP
Adherence, Discontinuation, and Switching of Biologic Therapies in Medicaid Enrollees with Rheumatoid Arthritis
Pengxiang Li, PhD, Marissa A. Blum, MD, Joan Von Feldt, MD, Sean Hennessy, PharmD. PhD, Jalpa A. Doshi, PhD
Measuring patient anxiety in primary care: Rasch analysis of the 6-item Spielberger State Anxiety Scale Helen Court, PhD, Katy Greenland, PhD, Thomas H. Margrain, PhD
Persistence patterns with oral antidiabetes drug treatment in newly treated patients – A population-based study
Jean-Pierre Grégoire, PhD, Caroline Sirois, MSc, Guillaume Blanc, Paul Poirier, MD, PhD, and Jocelyne Moisan, PhD
Medical Services Utilization and Expenditure of Obesity-related Disorders in Taiwanese Adults
Nain-Feng Chu, Shu-Chuan Wang, Hsin-Yi Chang, Der-Min Wu
POLICY ANALYSIS
How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma
Chabot Isabelle Ph.D., Rocchi Angela M.Sc.
The Impact of Value-Based Benefit Design on Adherence to Diabetes Medications: A Propensity Score Weighted Difference in Difference Evaluation
Feng Zeng, Ph.D., Jae Jin An, Ph.D., Robert Scully, M.D., Christina Barrington, Pharm.D., Bimal V Patel, Pharm.D., M.S., Michael B Nichol, Ph.D.
Quantification of the Potential Impact of Cost-effectiveness Thresholds on Dutch Drug Expenditures using Retrospective Analysis
Maarten J Postma, Adriaan Broere, Cornelis Boersma
Value in Health Main
Page
|
